American journal of cancer research最新文献

{"title":"Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer with <i>BRAF</i>-mutations: a retrospective study.","authors":"Xu Sun, Xiaona Meng, Qike Wang, Lu Zhang, Xiaolin Yu, He Zhang, Huaimin Liu","doi":"10.62347/MVNL2093","DOIUrl":"10.62347/MVNL2093","url":null,"abstract":"<p><strong>Objectives: </strong>To characterize the clinical features of non-small cell lung cancer (NSCLC) harboring BRAF mutations and to evaluate the effects of first-line chemotherapy combined with immunotherapy versus targeted therapy.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with BRAF-mutated NSCLC diagnosed between January 2017 and June 2023 at the Affiliated Cancer Hospital of Zhengzhou University. A total of 120 patients were included, with an overall BRAF mutation frequency of 0.9%. Among the mutations detected, the Val600Glu (V600E) substitution constituted 54.2% of cases. Clinical characteristics were compared between V600E and non-V600E subgroups, and treatment efficacies were analyzed.</p><p><strong>Results: </strong>Ninety-five patients received first-line treatment. The overall median progression-free survival (mPFS) was 8.77 months, and the median overall survival (mOS) was 13.30 months. First-line chemotherapy combined with immunotherapy resulted in longer mPFS (17.17 vs. 9.03 months, P = 0.573) and mOS (17.50 vs. 16.07 months, P = 0.376) compared with targeted therapy using BRAF and MEK inhibitors. In addition, patients with V600E mutations exhibited a trend toward longer mPFS compared to those with non-V600E mutations (9.73 vs. 6.77 months, P = 0.244).</p><p><strong>Conclusions: </strong>Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3533-3545"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNF200 enhances radiotherapy sensitivity by modulating PD-L1 stability in tumor-associated macrophages of lung cancer.","authors":"Hongbo Xu, Feng Cai, Lu Xu, Dengsheng Jiang, Gengming Wang, Xianwen Zhang, Yajun Zhang","doi":"10.62347/BIQP4822","DOIUrl":"10.62347/BIQP4822","url":null,"abstract":"<p><p>Radiotherapy is a cornerstone treatment for lung cancer; however, enhancing its efficacy and overcoming immune escape mechanisms - particularly those mediated by tumor-associated macrophages (TAMs) expressing programmed death-ligand 1 (PD-L1) - remain significant challenges. The E3 ubiquitin ligase RNF200 has been implicated in the regulation of PD-L1 expression, yet its role in the context of radiotherapy is not well understood. To address this, non-small cell lung cancer (NSCLC) tissue samples from patients with and without prior radiotherapy were analyzed for RNF200 and PD-L1 expression using quantitative RT-PCR and Western blotting. Additionally, RAW264.7 macrophages were subjected to ionizing radiation and genetically manipulated to assess the impact of RNF200 on PD-L1 expression and stability through co-immunoprecipitation and ubiquitination assays. Co-culture experiments with macrophages and lung cancer cells were performed to evaluate the influence of RNF200 on radiotherapy sensitivity. In NSCLC tissues and macrophages, radiotherapy was found to downregulate RNF200 expression while upregulating PD-L1 expression. Overexpression of RNF200 led to marked suppression of PD-L1 expression, whereas RNF200 knockdown produced the opposite effect. Co-immunoprecipitation and ubiquitination assays revealed that RNF200 physically interacted with PD-L1 and promoted its polyubiquitination and proteasomal degradation. Furthermore, co-culture studies demonstrated that macrophages overexpressing RNF200 enhanced the sensitivity of lung cancer cells to radiotherapy, as evidenced by reduced proliferation, increased necrosis, and decreased secretion of transforming growth factor beta TGF-β. Collectively, these findings indicate that RNF200 enhances radiotherapy sensitivity in lung cancer by regulating PD-L1 expression through ubiquitination. Targeting RNF200 may represent a promising strategy to improve the efficacy of radiotherapy in lung cancer treatment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3449-3459"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic value of serological markers in pancreatic neuroendocrine tumors: a single-center retrospective study.","authors":"Renrui Wan, Junfeng Wang, Ping Xie, Xiaochang Wu, Kun Guo","doi":"10.62347/HTDK5833","DOIUrl":"10.62347/HTDK5833","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics, diagnostic methods, treatment strategies and prognostic factors of pancreatic neuroendocrine tumors (pNETs).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 43 pNET patients treated at Huzhou Central Hospital from January 2003 to December 2023. The data included age, gender, function, tumor location, tumor size, pathological characteristics, lymph nodes, metastasis, and treatment. Association of these factors with pNET prognosis was proven by univariate analysis and multivariate analysis.</p><p><strong>Results: </strong>The incidence of G3 tumors in this group of advanced patients was relatively high (P=0.001). Meanwhile, elevated CA125 was commonly seen in the advanced stage (P=0.045), and surgeries occurred more frequently in the early stage (P=0.003). In addition, the positive expression of CD56 in low-grade tumors was relatively high (P=0.014). The incidence of non-functional tumors larger than 2 cm was high (P=0.015). Univariate Cox regression revealed that tumor size >2 cm, G3 grade, liver metastasis, advanced stage, lymph node metastasis and invasion were risk factors. Multivariate analysis revealed that G3 grade, liver metastasis and advanced stage were independent influencing factors for disease progression.</p><p><strong>Conclusion: </strong>pNETs are heterogeneous tumors. Pathological grade, metastatic status, and serological markers may assist in diagnosis and prognosis assessment, aiding individualized clinical management.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3546-3556"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on serum tRF-30-RRJ89O9NF5W8 as a potential biomarker for clinical diagnosis of gastric cancer.","authors":"Zhihan Zhang, Chunyan Mao, Yi Wu, Yin Wang, Hui Cong","doi":"10.62347/AIID7730","DOIUrl":"10.62347/AIID7730","url":null,"abstract":"<p><p>Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. In this study, our objective was to identify a specific tRNA-derived small RNA (tsRNA) as a biomarker for GC. We developed and validated a methodology to detect the expression level of tRF-30-RRJ89O9NF5W8 in the serum of GC patients. The results showed that the expression of tRF-30-RRJ89O9NF5W8 was significantly downregulated in the serum of GC patients and increased after radical surgery. Clinicopathological correlation analysis revealed that its expression level was closely associated with TNM stage, T stage, and neural/vascular invasion. Compared with existing GC diagnostic markers, tRF-30-RRJ89O9NF5W8 demonstrated superior diagnostic performance, effectively distinguishing GC patients from those with gastritis and healthy controls. These findings suggest that tRF-30-RRJ89O9NF5W8 may serve as a promising candidate diagnostic biomarker for GC and provide theoretical support for its potential as a therapeutic target.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3486-3499"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo antibody library screening identifies PKM2-targeting M1 antibody with antitumor activity in melanoma.","authors":"Hyukmin In, Yong Hwan Choi, Sunghyun Kang, Kyung Ho Han","doi":"10.62347/PSJY2877","DOIUrl":"10.62347/PSJY2877","url":null,"abstract":"<p><p>In this study, we introduce an innovative in vivo antibody screening method to identify antibodies that can inhibit melanoma cell growth and induce apoptosis. By using a lentiviral ScFv library, we developed a platform that allows for the direct suppression of melanoma cell proliferation within a living mouse model. Through this approach, we identified the M1 antibody, which targets PKM2, a key protein involved in tumor progression. The M1 antibody was found to significantly inhibit melanoma cell growth by disrupting the function of PKM2. Although PKM2 is widely recognized as an important factor in various cancers, no commercial therapeutic agents currently target this protein. Our findings indicate that the in vivo antibody screening method is a reliable and effective approach for isolating antibodies for melanoma therapy. Moreover, the M1 antibody shows great potential as a promising candidate for developing novel treatments for human melanoma.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3460-3470"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of monocytes in cancer.","authors":"Xinyue Zhang, Sitong Chen, Miao Shi, Jinjin Lou, Qichen Huang, Chunyan Li, Yanyan Huang, Liyun Xu","doi":"10.62347/CUTM4281","DOIUrl":"10.62347/CUTM4281","url":null,"abstract":"<p><p>Monocytes, a crucial element of the innate immune system, act as the primary cells in the body's immune response. Approved by the International Federation for Immunology in 2010, monocytes are categorized into three subsets based on the degree of cell surface molecule expression: classical monocytes, intermediate monocytes, and non-classical monocytes. Generally, different monocyte subsets have diverse responsibilities and can mutually transform to maintain the stability of the internal environment. Distinctions in functional characteristics and associations with diseases have been identified among the various monocyte subsets. This review aims to describe the expression and functions of monocytes in detail and discuss their roles in cancer immunity, which offers a novel approach for the diagnosis, treatment, and prognosis of tumors by exploring and summarizing the distribution of monocyte subsets in tumors. By delving into the distribution and functional characteristics of different monocyte subsets in tumors, it holds the promise of guiding individualized therapies and more precise tumor management.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3359-3375"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.","authors":"Lori A Leslie, John H Baird, Ian W Flinn, Michael Tees, Daanish Hoda, Abhinav Deol, Patricia Young, Brian McClune, Indumathy Varadarajan, James Essell, Suzanne Fanning, Gary Simmons, William Clark, Aaron P Rapoport, Tulio E Rodriguez, Joshua N Winters, Madison Davis, Harry M Miao, Markqayne Ray, Xiang Fang, Jenny J Kim, Olalekan O Oluwole","doi":"10.62347/GJNN1023","DOIUrl":"10.62347/GJNN1023","url":null,"abstract":"<p><p>ZUMA-24 is a Phase 2, open-label, multicenter study that investigated safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, administered in the outpatient setting to patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) with ≥1 prior lines of therapy. Patients underwent leukapheresis and received lymphodepleting chemotherapy, axi-cel infusion (2×10⁶ CAR T cells/kg), and prophylactic steroids. Patients were monitored daily ≥7 days after infusion per institutional outpatient monitoring guidelines. The primary endpoint was incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs). Median follow-up was 13 months for 30 patients treated with outpatient axi-cel. Grade 1-2 CRS was reported in 90% of patients, with no grade ≥3 CRS. NEs of any grade were reported in 80% of patients (grade ≥3, 23%; no patients died due to NEs). Median time to onset was 4 days for CRS and 7 days for NEs, with a median duration of 5 days and 6 days, respectively. All patients experienced AEs of any grade (grade ≥3, 83%). After axi-cel, 93% of patients were hospitalized, with 4 days median time to first hospitalization (8 days median stay), and 4 patients (13%) were admitted to the ICU (for 2-7 days). Among patients evaluable for efficacy (n=29), the objective response rate was 93% (complete response, 76%), with a median duration of response of 11.4 months. These results support safety and feasibility of outpatient administration of axi-cel. This trial is registered at ClinicalTrials.gov: #NCT05459571.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3417-3433"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating early-stage nasopharyngeal carcinoma from adenoidal hypertrophy via SLC40A1 expression and developing a prognostic model for disease progression.","authors":"Hongwei Wang, Suqing Qi, Chaobing Liu, Zhenhua Qiao, Chao Zhang","doi":"10.62347/ZBIH5385","DOIUrl":"10.62347/ZBIH5385","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression and diagnostic utility of solute carrier family 40 member 1 (SLC40A1) in differentiating early diagnosis of nasopharyngeal carcinoma (NPC) from adenoid hypertrophy (AH), and to develop a prognostic prediction model based on its expression.</p><p><strong>Methods: </strong>Public databases were used to analyze SLC40A1 expression in head and neck squamous cell carcinoma (HNSC) and its association with prognosis, pathological staging, and immune infiltration. A total of 102 NPC patients, 97 AH patients, and 101 healthy controls were enrolled between October 2021 and October 2023. SLC40A1 expressions in tissues and serum were assessed via real-time reverse transcription polymerase chain reaction and Western blotting. Associations with clinicopathological features were evaluated. Receiver operating characteristic (ROC) curves evaluated diagnostic performance. Logistic regression identified prognostic factors, and a predictive model was constructed.</p><p><strong>Results: </strong>Bioinformatics analysis indicated downregulated SLC40A1 in HNSC, negatively associated with tumor (T) stage and distant metastasis (M) stage. Clinical validation showed significantly lower SLC40A1 mRNA and protein levels in NPC compared to AH and controls, with negative correlation to Epstein-Barr virus (EBV) infection (all P<0.05). Serum SLC40A1 mRNA demonstrated 90.20% sensitivity and 62.38% specificity for NPC diagnosis. When combined with EBV DNA, it yielded an improved diagnostic performance (AUC=0.913). Tumor diameter >5 cm and lymph nodes ≥2 were independent risk factors for NPC progression, while high SLC40A1 expression was protective (OR=0.140, 95% CI: 0.028-0.700). The final model achieved 91.67% sensitivity and 72.00% specificity (AUC=0.863).</p><p><strong>Conclusion: </strong>SLC40A1 is significantly downregulated in NPC and may serve as a diagnostic and prognostic biomarker, especially when combined with EBV status.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3434-3448"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic immune-inflammation index and lymphocyte-to-monocyte ratio predict recurrence after radical surgery for stage I/II endometrial cancer.","authors":"Xinxin Hu, Liangyu Zhou, Ruyin Lin","doi":"10.62347/ZWXU9375","DOIUrl":"10.62347/ZWXU9375","url":null,"abstract":"<p><p>Early-stage endometrial cancer (stage I/II) is often treated successfully with radical surgery, but recurrence remains a concern in some patients. Identifying reliable biomarkers for recurrence risk is essential for improving post-surgical management. This study investigated the prognostic significance of systemic immune-inflammation index (SII) and lymphocyte-to-monocyte ratio (LMR) in predicting recurrence after radical surgery for stage I/II endometrial cancer. This retrospective cohort study analyzed 950 patients who underwent radical surgery for stage I/II endometrial cancer between March 2015 and October 2024. Patients were classified into recurrence (n=95) and non-recurrence (n=855) groups. The predictive value of LMR and SII was assessed using logistic regression. Predictive accuracies were evaluated using the area under the curve (AUC). Additionally, an external validation cohort consisting of 495 patients, who met the same inclusion criteria, was used to further validate the predictive model. LMR and SII were significantly associated with cancer recurrence. High SII and low LMR were predominantly observed in the recurrence group, demonstrating substantial predictive power. Multivariate logistic regression revealed that LMR was the strongest independent predictor of recurrence (OR=1.795, 95% CI, 1.417-2.274). The combined model of LMR and SII achieved an AUC of 0.876, highlighting its excellent predictive performance. SII and LMR are valuable systemic immune-inflammation indices for predicting recurrence in stage I/II endometrial cancer patients after radical surgery.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3471-3485"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of CAR-T therapy based on metabolic remodeling of the tumor immune microenvironment in diffuse large B-cell lymphoma.","authors":"Lijuan Yuan, Chunxiao Wang, Lifa Du, Weizhi Chen, Xiaomei Zhang","doi":"10.62347/XWSP9750","DOIUrl":"10.62347/XWSP9750","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin's lymphoma, faces the severe challenge of relapsed/refractory cases, with limited efficacy of existing therapies such as the R-CHOP regimen and second-line treatment plans. There is an urgent need for innovative treatment strategies. CAR-T therapy has shown revolutionary potential in the treatment of DLBCL, but its efficacy is limited by immune suppression and metabolic competition mediated by the tumor microenvironment (TME). Immunosuppressive cells and cytokines in the TME lead to the exhaustion of CAR-T cell functions, while metabolic competition puts CAR-T cells at a disadvantage in the uptake of key metabolites, limiting their proliferation and effector functions. Metabolic reprogramming, as a core mechanism of TME regulation, connects the functions of tumor cells and immune cells and is a key hub for enhancing the efficacy of CAR-T therapy. Among them, low glucose levels in the TME can activate the glycolytic pathway of CAR-T cells, but also lead to mitochondrial dysfunction and reduced cytotoxicity. Targeting the metabolic remodeling of the TME, in combination with metabolic regulatory drugs and CAR-T synergy strategies, as well as the development and translation of drugs, is expected to significantly enhance the efficacy of CAR-T therapy in the treatment of DLBCL, bringing new hope to patients. Future research should further explore the specific mechanisms of metabolic reprogramming, optimize the design and application of metabolic regulatory drugs, and accelerate the clinical translation of drugs to achieve the maximum potential of CAR-T therapy in the treatment of DLBCL.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3338-3358"},"PeriodicalIF":2.9,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}